{"id":8216,"date":"2020-07-06T12:00:20","date_gmt":"2020-07-06T16:00:20","guid":{"rendered":"http:\/\/localhost:10028\/uncategorized\/history-of-us-pharmaceutical-lawsuits\/"},"modified":"2022-08-18T21:16:09","modified_gmt":"2022-08-19T01:16:09","slug":"ilac-dava-tarihcesi","status":"publish","type":"post","link":"https:\/\/napolilaw.lemonadestand.org\/tr\/article\/ilac-dava-tarihcesi\/","title":{"rendered":"ABD \u0130la\u00e7 Davalar\u0131n\u0131n Tarih\u00e7esi"},"content":{"rendered":"

\u0130la\u00e7 davalar\u0131, ABD hukuk tarihi boyunca bir\u00e7ok milyon ve hatta milyar dolarl\u0131k uzla\u015fmayla sonu\u00e7land\u0131. Dava a\u00e7mak, h\u0131zla zengin olma plan\u0131 de\u011fildir; Birincisi, s\u00fcre\u00e7 nadiren h\u0131zl\u0131d\u0131r. Baz\u0131 durumlarda, dava a\u00e7mak, \u00fcreticileri ila\u00e7lar\u0131n\u0131n zararl\u0131 etkilerinden sorumlu tutman\u0131n ve ihmallerinden kaynaklanan durumlar\u0131 tedavi etmek i\u00e7in mali kaynaklar elde etmenin tek yolu olabilir.<\/span><\/p>\n

\u00c7o\u011fu zaman, \u00fcreticiler bir ilac\u0131n veya t\u0131bbi cihaz\u0131n uzun vadeli veya tehlikeli yan etkileri konusunda doktorlar\u0131 ve hastalar\u0131 uyarmad\u0131\u011f\u0131nda dava a\u00e7\u0131l\u0131r. \u00dcreticiler bu bilgileri saklad\u0131\u011f\u0131nda, doktorlar hastalar\u0131yla \u00fcr\u00fcn\u00fcn yararlar\u0131 ve riskleri hakk\u0131nda ileti\u015fim kuramazlar. Sonu\u00e7 olarak, hastalara \u00fcr\u00fcn re\u00e7ete edilecektir ve sonunda ciddi sa\u011fl\u0131k sorunlar\u0131 ya\u015fayabilirler.<\/span><\/p>\n

Farmas\u00f6tik davalar\u0131n\u0131n neden ortaya \u00e7\u0131kt\u0131\u011f\u0131na ve son zamanlarda farmas\u00f6tik ihmal vakalar\u0131na ili\u015fkin baz\u0131 tarih\u00e7eleri burada bulabilirsiniz.<\/span><\/p>\n

ABD'de Do\u011frudan T\u00fcketiciye \u0130la\u00e7 Reklamc\u0131l\u0131\u011f\u0131<\/span><\/h2>\n

ABD <\/span>birka\u00e7 \u00fclkeden biri<\/span><\/a> farmas\u00f6tik ila\u00e7lar i\u00e7in do\u011frudan t\u00fcketiciye farmas\u00f6tik reklamc\u0131l\u0131\u011fa (DTCPA) izin veren. \u0130la\u00e7lar i\u00e7in do\u011frudan t\u00fcketiciye y\u00f6nelik reklamlar, piyasada yaln\u0131zca birka\u00e7 t\u00fcr ila\u00e7 varken yirminci y\u00fczy\u0131l\u0131n ba\u015flar\u0131nda ba\u015flad\u0131.<\/span><\/p>\n

1905 y\u0131l\u0131nda Amerikan Tabipler Birli\u011fi taraf\u0131ndan atanan Eczac\u0131l\u0131k ve Kimya Konseyi, <\/span>cesareti k\u0131r\u0131lm\u0131\u015f DTCPA<\/span><\/a> halka pazarlanan ila\u00e7lar\u0131 "etik d\u0131\u015f\u0131" olarak etiketleyerek, yaln\u0131zca do\u011frudan t\u0131p uzmanlar\u0131na pazarlanan ila\u00e7lar\u0131 destekleyerek. Ancak, DTCPA hi\u00e7bir zaman yasa d\u0131\u015f\u0131 yap\u0131lmad\u0131.<\/span><\/p>\n

1906'da Saf G\u0131da ve \u0130la\u00e7 Yasas\u0131'n\u0131n kabul edilmesi, hastalar\u0131 ila\u00e7lar\u0131n etkileri konusunda e\u011fitmek, i\u00e7erik maddelerini a\u00e7\u0131klamak ve uygun etiketlemeyi dahil etmek ve ilac\u0131n etkilerini yanl\u0131\u015f tan\u0131tmamak i\u00e7in federal standartlar yaratt\u0131. Daha sonra, 1938 ve 1951'deki ek d\u00fczenlemeler, t\u00fcketicileri korumak i\u00e7in reklamlar\u0131n\u0131, da\u011f\u0131t\u0131mlar\u0131n\u0131 ve kullan\u0131mlar\u0131n\u0131 d\u00fczenlemek i\u00e7in ila\u00e7lar\u0131 ek federal k\u0131s\u0131tlamalar alt\u0131na ald\u0131.<\/span><\/p>\n

\u00dcretici reklamlar\u0131n\u0131n \u00e7o\u011fu ba\u015flang\u0131\u00e7ta hekimleri hedef alsa da, do\u011frudan t\u00fcketiciye y\u00f6nelik reklamlar \u00f6nemli \u00f6l\u00e7\u00fcde artt\u0131. Bug\u00fcn, bu reklamlar, ila\u00e7 \u015firketlerinin promosyonlara harcad\u0131klar\u0131 miktar\u0131n yakla\u015f\u0131k y\u00fczde 40'\u0131n\u0131 olu\u015fturuyor. Ve federal y\u00f6nergeler, ila\u00e7lar\u0131 t\u00fcketiciler i\u00e7in g\u00fcvenli tutmak i\u00e7in tasarlanm\u0131\u015f olsa da, zararl\u0131 ila\u00e7lar\u0131n halka ula\u015fmas\u0131n\u0131 durdurmak i\u00e7in her zaman yeterli de\u011fildir.<\/span><\/p>\n

Diyabet, kolesterol, erektil disfonksiyon, depresyon, a\u011fr\u0131 ve di\u011fer bir dizi durumu tedavi eden re\u00e7eteli ila\u00e7lar\u0131n reklam\u0131n\u0131 yapmak i\u00e7in kitle ileti\u015fim ara\u00e7lar\u0131n\u0131n artan kullan\u0131m\u0131 nedeniyle, t\u00fcketiciler genellikle kendi kendine te\u015fhis koyarlar. Bu, bir\u00e7ok t\u00fcketicinin ihtiya\u00e7 duymad\u0131klar\u0131 re\u00e7eteli ila\u00e7lar\u0131 sat\u0131n almas\u0131na yol a\u00e7ar.<\/span><\/p>\n

Neyse ki, ABD sa\u011fl\u0131k sistemi son otuz y\u0131lda hastalar\u0131n tedavi se\u00e7enekleri ve sat\u0131n alma kararlar\u0131 hakk\u0131nda bilgi edinme haklar\u0131n\u0131 g\u00fcvence alt\u0131na almak i\u00e7in daha da \u00f6nemli reformlar yapt\u0131.<\/span><\/p>\n

Do\u011frudan t\u00fcketiciye y\u00f6nelik farmas\u00f6tik reklamc\u0131l\u0131\u011f\u0131 ve ABD'de her y\u0131l kullan\u0131lan y\u00fcksek hacimli ila\u00e7 kombinasyonu, ila\u00e7lar\u0131 yanl\u0131\u015f tan\u0131tt\u0131\u011f\u0131nda veya zararl\u0131 etkileri tam olarak a\u00e7\u0131klanmad\u0131\u011f\u0131nda, belki de di\u011fer \u00fclkelerde oldu\u011fundan daha fazla, \u00fcreticileri ve farmas\u00f6tikleri davalara a\u00e7\u0131k hale getiriyor. .<\/span><\/p>\n

Son Zamanlardaki En B\u00fcy\u00fck \u0130la\u00e7 Davalar\u0131<\/span><\/h2>\n

1991'den 2017'ye kadar olan yakla\u015f\u0131k otuz y\u0131lda, ila\u00e7 \u00fcreticileri, yanl\u0131\u015f reklamdan kan\u0131tlanm\u0131\u015f yan etkilere ili\u015fkin bilgileri saklamaya kadar her \u015fey i\u00e7in toplam $38,6 milyar \u00f6deyerek federal ve eyalet h\u00fck\u00fcmetleri nezdinde 412 vakay\u0131 \u00e7\u00f6z\u00fcme kavu\u015fturdu.<\/span><\/p>\n

ABD'deki en b\u00fcy\u00fck ila\u00e7 anla\u015fmalar\u0131ndan ikisi GlaxoSmithKline ve Takeda Pharmaceuticals \u015firketlerini i\u00e7eriyordu.<\/span><\/p>\n

GlaxoSmithKline: $3 milyar<\/span><\/h3>\n

2012 y\u0131l\u0131nda GlaxoSmithKline (GSK) yerle\u015fti <\/span>ABD'deki en b\u00fcy\u00fck sa\u011fl\u0131k davas\u0131<\/span><\/a> $3 milyar \u00f6deme ile.<\/span><\/p>\n

GSK, aralar\u0131nda Avandia, Paxil ve Wellbutrin'in de bulundu\u011fu baz\u0131 re\u00e7eteli ila\u00e7lar\u0131 yasa d\u0131\u015f\u0131 bir \u015fekilde tan\u0131tmakla su\u00e7land\u0131. \u015eirket, g\u00fcvenlik verilerinin bir k\u0131sm\u0131n\u0131 FDA'ya bildirmeyi ba\u015faramad\u0131 ve ayr\u0131ca Medicaid \u0130la\u00e7 \u0130ndirim Program\u0131 kapsam\u0131ndaki indirimleri eksik \u00f6demek i\u00e7in yanl\u0131\u015f ila\u00e7 fiyatlar\u0131 verdi.<\/span><\/p>\n

Ek olarak \u015firket, antidepresan ila\u00e7lar\u0131n\u0131 (Paxil ve Wellbutrin) yanl\u0131\u015f markala\u015ft\u0131rd\u0131 ve ayr\u0131ca sa\u011fl\u0131k hizmeti sa\u011flay\u0131c\u0131lar\u0131n\u0131 hastalar\u0131na endikasyon d\u0131\u015f\u0131 kullan\u0131mlar i\u00e7in tavsiye ettikleri i\u00e7in \u00f6d\u00fcllendirdi.<\/span><\/p>\n

Ayr\u0131ca \u015firket, diyabeti tedavi etmeyi ama\u00e7layan Avandia i\u00e7in g\u00fcvenlik verileri \u00fcretemedi ve bu da bir\u00e7ok hastay\u0131 ilac\u0131n kardiyovask\u00fcler g\u00fcvenli\u011fi konusunda endi\u015felendirdi.<\/span><\/p>\n

Takeda \u0130la\u00e7: $2,4 milyar<\/span><\/h3>\n

2015 y\u0131l\u0131nda Takeda \u0130la\u00e7'a ila\u00e7 davas\u0131 a\u00e7\u0131ld\u0131. \u015eirket, oral diyabet ilac\u0131 Actos ile ilgili mesane kanseri risklerini gizlemekten su\u00e7lu bulundu. <\/span>\u015eirket yerle\u015fti<\/span><\/a> $2,4 milyar \u00f6deyerek 8.000'den fazla federal ve eyalet davas\u0131.<\/span><\/p>\n

Actos, 1999 y\u0131l\u0131nda FDA taraf\u0131ndan onayland\u0131ktan sonra \u015firketin en \u00e7ok satan ilac\u0131 oldu. GlaxoSmithKline'\u0131n diyabetik ilac\u0131 (Avandia), kardiyovask\u00fcler g\u00fcvenlik endi\u015feleri nedeniyle k\u0131s\u0131tland\u0131ktan sonra daha pop\u00fcler hale geldi.<\/span><\/p>\n

Avandia'n\u0131n k\u0131s\u0131tlanmas\u0131ndan sonra Takeda, inme veya kalp krizi riskini art\u0131rmadan kan \u015fekerini d\u00fc\u015f\u00fcrebilece\u011fini iddia ederek en \u00e7ok satan ilac\u0131n\u0131n reklam\u0131n\u0131 yapt\u0131. Ancak \u015firkete, ilac\u0131n iddia edilen faydalar\u0131 konusunda halk\u0131 yan\u0131ltmaktan ve yan etkilerini g\u00f6zden ka\u00e7\u0131rmaktan dava a\u00e7\u0131ld\u0131.<\/span><\/p>\n

G\u00fcncel \u0130la\u00e7 Davalar\u0131<\/span><\/h2>\n

\u0130la\u00e7 dava avukatlar\u0131<\/span><\/a> at Napoli Shkolnik are currently involved in several lawsuits involving the misrepresentation and resulting harmful effects of pharmaceuticals.\u00a0<\/span><\/p>\n

Opioid Davalar\u0131<\/span><\/h3>\n

Son birka\u00e7 on y\u0131lda geli\u015fen ABD opioid salg\u0131n\u0131, art\u0131k bireyler ve topluluklar i\u00e7in ciddi olumsuz sonu\u00e7lara yol a\u00e7maktad\u0131r. Halihaz\u0131rda ila\u00e7 \u015firketleri, dispanserler ve perakende eczaneler aleyhine opioidle ilgili davalar devam etmektedir.<\/span><\/p>\n

Napoli Shkolnik'in Opioid Deneme Ekibi, 2019 sonbahar\u0131nda Ohio'daki d\u00f6n\u00fcm noktas\u0131 niteli\u011findeki $320 milyon yerle\u015fim biriminin bir par\u00e7as\u0131yd\u0131. \u015eirket ayr\u0131ca, COVID-19 nedeniyle ertelenmeden \u00f6nce Mart 2020'de New York'ta yap\u0131lmas\u0131 planlanan bir sonraki opioid deneme turunu y\u00f6netiyor.\u00a0<\/span><\/p>\n

Opioidler, h\u00fccrelerinizdeki opioid resept\u00f6rleri ile etkile\u015fime giren bir a\u011fr\u0131 kesici ila\u00e7 grubudur. Bir doktor taraf\u0131ndan \u00f6nerildi\u011fi \u015fekilde ve k\u00fc\u00e7\u00fck dozlarda kullan\u0131ld\u0131\u011f\u0131nda, bu ila\u00e7lar akut a\u011fr\u0131n\u0131n kontrol alt\u0131na al\u0131nmas\u0131na yard\u0131mc\u0131 olabilir. Bununla birlikte, ba\u011f\u0131ml\u0131l\u0131k yap\u0131c\u0131 yap\u0131lar\u0131 y\u0131llard\u0131r ciddi \u015fekilde yeterince temsil edilmedi ve bu da a\u015f\u0131r\u0131 re\u00e7ete, ba\u011f\u0131ml\u0131l\u0131k ve y\u0131k\u0131c\u0131 say\u0131da a\u015f\u0131r\u0131 doz \u00f6l\u00fcm\u00fcyle sonu\u00e7land\u0131.<\/span><\/p>\n

Opioid davalar\u0131<\/span><\/a> hepsi, Amerika Birle\u015fik Devletleri'ni kas\u0131p kavuran opioid salg\u0131n\u0131ndan opioid \u00fcreticilerini ve distrib\u00fct\u00f6rlerini sorumlu tutmay\u0131 ama\u00e7l\u0131yor.<\/span><\/p>\n

Elmiron Davalar\u0131<\/span><\/h3>\n

Janssen Pharmaceuticals, t\u00fcketicileri Elmiron ilac\u0131n\u0131n neden oldu\u011fu potansiyel g\u00f6rme kayb\u0131 hakk\u0131nda bilgilendirmemekle su\u00e7lan\u0131yor.<\/span><\/p>\n

Son ara\u015ft\u0131rmalara g\u00f6re interstisyel sistit ve buna ba\u011fl\u0131 mesane a\u011fr\u0131s\u0131 tedavisinde kullan\u0131lan ila\u00e7, <\/span>geri d\u00f6n\u00fc\u015f\u00fc olmayan g\u00f6rme hasar\u0131na neden olabilir<\/span><\/a> ok\u00fcler toksisitesi nedeniyle. 2019'da Amerikan Oftalmoloji Akademisi'nde sunulan ara\u015ft\u0131rma, ilac\u0131 alan hastalar\u0131n toksisite belirtileri g\u00f6sterdi\u011fini ortaya koydu.<\/span><\/p>\n

Elmiron kulland\u0131ysan\u0131z ve g\u00f6rme kayb\u0131 ya\u015fad\u0131ysan\u0131z, tazminat alma hakk\u0131n\u0131z olabilir. T\u00fcketiciler sa\u011fl\u0131klar\u0131 hakk\u0131nda bilin\u00e7li kararlar alma hakk\u0131na sahiptir ve <\/span>Elmiron davas\u0131<\/span><\/a> hastalara bu bilgi ve hakk\u0131 vermemekten Janssen Pharmaceuticals'\u0131 sorumlu tutuyor.<\/span><\/p>\n

Hatal\u0131 \u00fcretilmi\u015f veya etkisi hakk\u0131nda bilgilendirilmedi\u011finiz bir ilac\u0131 ald\u0131ktan sonra ciddi sa\u011fl\u0131k sorunlar\u0131 ya\u015f\u0131yorsan\u0131z, sesinizi y\u00fckselterek ila\u00e7 \u015firketlerinin sorumlu tutulmas\u0131na yard\u0131mc\u0131 olabilirsiniz.<\/span><\/p>","protected":false},"excerpt":{"rendered":"

\u0130la\u00e7 davalar\u0131, ABD hukuk tarihi boyunca bir\u00e7ok milyon ve hatta milyar dolarl\u0131k uzla\u015fmayla sonu\u00e7land\u0131. Dava a\u00e7mak, h\u0131zla zengin olma plan\u0131 de\u011fildir; Birincisi, s\u00fcre\u00e7 nadiren h\u0131zl\u0131d\u0131r\u2026.<\/p>","protected":false},"author":3,"featured_media":8217,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[776],"tags":[],"class_list":["post-8216","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharmaceutical-litigation"],"acf":[],"page_builder_type":"gutenberg","gutenberg_data":[],"_links":{"self":[{"href":"https:\/\/napolilaw.lemonadestand.org\/tr\/wp-json\/wp\/v2\/posts\/8216","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/napolilaw.lemonadestand.org\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/napolilaw.lemonadestand.org\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/napolilaw.lemonadestand.org\/tr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/napolilaw.lemonadestand.org\/tr\/wp-json\/wp\/v2\/comments?post=8216"}],"version-history":[{"count":0,"href":"https:\/\/napolilaw.lemonadestand.org\/tr\/wp-json\/wp\/v2\/posts\/8216\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/napolilaw.lemonadestand.org\/tr\/wp-json\/wp\/v2\/media\/8217"}],"wp:attachment":[{"href":"https:\/\/napolilaw.lemonadestand.org\/tr\/wp-json\/wp\/v2\/media?parent=8216"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/napolilaw.lemonadestand.org\/tr\/wp-json\/wp\/v2\/categories?post=8216"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/napolilaw.lemonadestand.org\/tr\/wp-json\/wp\/v2\/tags?post=8216"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}